MET Exon 14 Skipping Mutation in NSCLC: From Genomic Discovery to Biomarker-Guided Therapeutic Innovation
The MET exon 14 skipping mutation is an important target for the precision treatment of NSCLC, and MET-TKIs have remarkable efficacy but a prominent problem with drug resistance. The construction of a precision medicine system encompassing diagnosis, treatment, and drug resistance management through multi-omics research, technological innovation, and international collaboration is a key direction for improving prognosis.
Authors
- Qiufang Chen
- Xiang Huang
- Min Zhao
- Linjuan Wang
- Yue Qiu
- Shimei Zhang
Institutions
- First Affiliated Hospital of Xiamen University (CN)
- Children’s Hospital of Fudan University Xiamen Branch (CN)
- Xiamen Maternal and Child Health Hospital (CN)
Publication Details
- Journal
- Current Drug Targets
- Published
- 2026-01-22
- DOI
- https://doi.org/10.2174/0113894501409916251103161912
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00